Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Bioconjug Chem ; 28(7): 1801-1806, 2017 07 19.
Artigo em Inglês | MEDLINE | ID: mdl-28603971

RESUMO

Cell-penetrating peptides are receiving increasing attention as drug delivery tools, and the search for peptides with high cell-penetrating ability and negligible cytotoxicity has become a critical research topic. Herein, cyclic α,α-disubstituted α-amino acids were introduced into arginine-rich peptides and an additional staple was provided in the side chain. The peptides designed in the present study showed more enhanced and prolonged cell-penetrating abilities than an arginine nonapeptide due to high resistance to protease and conformationally stable helical structures.


Assuntos
Aminoácidos Cíclicos , Arginina , Peptídeos Penetradores de Células/síntese química , Sistemas de Liberação de Medicamentos/métodos , Peptídeos/química , Peptídeos Penetradores de Células/química , Desenho de Fármacos , Estabilidade de Medicamentos , Células HeLa , Humanos , Relação Estrutura-Atividade
2.
In Vivo ; 38(4): 1882-1890, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38936947

RESUMO

BACKGROUND/AIM: Hypertension occurs frequently in patients taking pazopanib. Therefore, this study aimed to clarify the predictive factors for pazopanib-induced hypertension. PATIENTS AND METHODS: In total, 47 patients who started pazopanib treatment for renal cell carcinoma or soft tissue sarcoma during hospitalization at Kurume University Hospital from November 2012 to February 2020 were included in the study. Patient background factors associated with pazopanib-induced hypertension were analyzed using a logistic regression model. Subsequently, a time-dependent receiver operating characteristic (ROC) analysis was performed to evaluate changes in the predictive performance of predictors of pazopanib-induced hypertension over time. RESULTS: Logistic regression analysis showed that total bilirubin (t-bil) and sex are predictors of pazopanib-induced hypertension, along with systolic blood pressure (SBP) before pazopanib introduction. Additionally, evaluation of area under the curve (AUC) changes over time during the first 20 days of pazopanib treatment using time-dependent ROC showed that the AUC tended to be higher in the first half for SBP and in the second half for t-bil. Moreover, models including these two factors (SBP+t-bil and SBP+t-bil+sex) maintained a higher AUC from the early to late stages of the treatment period. CONCLUSION: Total bilirubin and sex can serve as predictors of pazopanib-induced hypertension. Total bilirubin may contribute to the prediction of the development of hypertension after day 5.


Assuntos
Hipertensão , Indazóis , Pirimidinas , Sulfonamidas , Humanos , Pirimidinas/efeitos adversos , Pirimidinas/uso terapêutico , Masculino , Feminino , Hipertensão/induzido quimicamente , Hipertensão/tratamento farmacológico , Sulfonamidas/efeitos adversos , Sulfonamidas/uso terapêutico , Pessoa de Meia-Idade , Idoso , Curva ROC , Inibidores da Angiogênese/efeitos adversos , Inibidores da Angiogênese/uso terapêutico , Adulto , Carcinoma de Células Renais/tratamento farmacológico , Fatores de Risco , Pressão Sanguínea/efeitos dos fármacos , Idoso de 80 Anos ou mais , Neoplasias Renais/tratamento farmacológico , Prognóstico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA